Navigation Links
Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
Date:8/29/2011

The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent. However, other earlier studies comparing EES with another first generation drug-eluting stent, sirolimus-eluting stent (SES), have only demonstrated the non-inferiority of EES; the superiority of EES relative to SES in terms of target-lesion revascularisation has not yet been investigated in adequately powered randomised controlled trials.

This has now been addressed in the Randomised Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET), a prospective randomised multicentre open label trial comparing EES with SES in daily clinical practice in Japan. The trial was performed in patients scheduled for percutaneous coronary intervention with drug-eluting stents, who were enrolled without any exclusion criteria. The primary efficacy endpoint was defined as any target-lesion revascularisation. The trial was a sequential non-inferiority and superiority study, which was powered for non-inferiority on the primary efficacy endpoint at one year after the index procedure.

Between February and July 2010, a total of 3206 patients were enrolled in the trial among 100 participating centres. Excluding nine patients who withdrew consent, 3197 patients were randomly assigned to receive either of the twp investigation stents.

An angiographic sub-study evaluating in-segment late lumen loss and angiographic restenosis rate at eight months included 571 patients. The study population included large proportions of patients with advanced age, diabetes and prior PCI. The two groups of patients were well balanced in terms of baseline clinical, angiographic and procedural characteristics.

Results of this large randomised trial comparing showed EES to be non-inferior to SES in terms of target-lesion revascularisation rate at one year and angiographic in-segment late loss at 8-12 months.

"One-year clinical outcome after both EES and SES use was excellent," said investigator Dr Takeshi Kimura from Kyoto University Hospital, Kyoto, Japan, "with low rate of target-lesion revascularisation and very low rate of stent thrombosis."

However, Dr Kimura cautioned about several limitations to the study. First, he said, although SES was not widely used at the time of the trial, it was the most widely used and most extensively studied first generation DES. Clinical outcome after SES implantation should be regarded as the benchmark for the current and future generation drug-eluting stents.

Second, despite the all-comers trial design, the study population actually enrolled seemed to represent relatively low-risk patients, resulting in event rates lower than anticipated. Future stent trials, he suggested, might focus more on complex patients, in whom coronary artery bypass grafting could be a reasonable alternative.

Dr Kimura also added that longer-term follow-up is important to address whether EES might affect the late adverse events beyond one year such as late restenosis and very late stent thrombosis.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-633-473-335
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
2. AMRI receives NIH contract award for development of pre-clinical drug candidates
3. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
4. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
5. PACS improves radiologists use of clinical decision support systems
6. Wake Forest Baptist conducts clinical study for insomnia using new technology
7. Damon Runyon Cancer Research Foundation awards $3.45 million to 9 top young clinical investigators
8. Neuralstem updates clinical trial progress
9. Universal flu vaccine clinical trials show promise
10. Pioneering stem cell bandage receives approval for clinical trial
11. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
(Date:12/8/2016)... Cincinnati, OH (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial planning services from offices headquartered in Hamilton County, is ... animal rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a ... clients in and around the Hancock County area, is announcing the launch of a ... Pantry. , The Hancock County Food Pantry has worked for more than 30 years ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... wrinkles and deep lines by smoothing and tightening the skin of the face ... there to address facial aging with very little downtime, Silhouette Instalift is a ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LITTLE FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL ... net income of $18,800,000, or $0.45 per diluted share, on ... the first quarter ended October 31, 2016. This compares with ... sales of $153,779,000 for the first quarter ended October 31, ... the first quarter ended October 31, 2016 to $21,323,000, or ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:12/7/2016)... 7, 2016 KEY FINDINGS ... such as reducing loss of blood during surgeries, ... arrests, rapid recovery after surgeries, and decreasing risks ... segmented into convective warming system, surface warming systems, ... reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology: